One previous study [22] concluded that G-CSF prophylaxis for all cycles of chemotherapy is more effective in patients with breast cancer, but associated with higher cost, when compared to the administration of prophylaxis solely for the first two cycles of chemotherapy. This evidence concerns the gene CSF3 and breast carcinoma.